EGG‑NEWS.com

Alveo Technologies has received a grant from the Centers for Disease Control to develop a rapid, molecular diagnostic test that would differentiate between influenza A and B and confirm H5 antigen in humans. The response by Alveo Technologies follows an open call for innovative test systems previously released by the Centers for Disease Control. The invitation to industry is regarded as a preemptive measure in the event that H5N1 emerges as a zoonotic infection requiring rapid, mass diagnosis at point-of-need.  The CDC recognized the need for prompt  diagnoses of A, B and A/H5 infections. 

Alveo has developed a portable molecular detection platform using isothermal Nucleic Acid Amplification Technology (NAAT) capable of differentiating among influenza A and B and confirming A/H5.  Deploying a rapid diagnostic system will reduce the need to submit specimens to regional diagnostic laboratories equipped with PCR, thereby reducing delays and providing clinicians with real-time diagnostic information to facilitate therapy.  Acquisition of data that can be transmitted through a cloud-base portal for analysis will facilitate epidemiologic investigations and allocation of resources.

Alveo will also obtain approval for a molecular test system for avian influenza H5, H7 and H9 in poultry to facilitate diagnosis of outbreaks and to expedite control measures.